Andres Maldonado
Stock Analyst at HC Wainwright & Co.
(2.75)
# 1,988
Out of 4,960 analysts
86
Total ratings
32.94%
Success rate
0.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Reiterates: Buy | $7 | $5.09 | +37.52% | 1 | Jul 9, 2025 | |
| IBRX ImmunityBio | Reiterates: Buy | $8 | $2.31 | +246.32% | 4 | Jun 4, 2025 | |
| AURA Aura Biosciences | Assumes: Buy | $22 | $6.55 | +235.88% | 1 | May 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $10 | $1.99 | +402.51% | 1 | May 15, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $50 → $40 | $9.79 | +308.58% | 2 | May 7, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $15 → $10 | $1.87 | +434.76% | 1 | May 7, 2025 | |
| ERAS Erasca | Reiterates: Buy | $6 | $1.60 | +275.00% | 10 | Apr 30, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $5.56 | +133.81% | 1 | Apr 30, 2025 | |
| STRO Sutro Biopharma | Reiterates: Neutral | $2 | $0.86 | +133.15% | 1 | Apr 29, 2025 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $3.11 | +639.55% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $26.92 | +178.66% | 13 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $7.20 | +400.00% | 14 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $2.08 | +188.46% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.32 | +1,036.36% | 16 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $4.32 | +478.70% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $35.49 | +40.88% | 13 | Nov 26, 2024 |
I-Mab
Jul 9, 2025
Reiterates: Buy
Price Target: $7
Current: $5.09
Upside: +37.52%
ImmunityBio
Jun 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.31
Upside: +246.32%
Aura Biosciences
May 28, 2025
Assumes: Buy
Price Target: $22
Current: $6.55
Upside: +235.88%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Buy
Price Target: $10
Current: $1.99
Upside: +402.51%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $9.79
Upside: +308.58%
TScan Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $1.87
Upside: +434.76%
Erasca
Apr 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Buy
Price Target: $13
Current: $5.56
Upside: +133.81%
Sutro Biopharma
Apr 29, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.86
Upside: +133.15%
Protara Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $23
Current: $3.11
Upside: +639.55%
Apr 28, 2025
Reiterates: Buy
Price Target: $75
Current: $26.92
Upside: +178.66%
Apr 3, 2025
Reiterates: Buy
Price Target: $36
Current: $7.20
Upside: +400.00%
Mar 26, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $2.08
Upside: +188.46%
Mar 12, 2025
Reiterates: Buy
Price Target: $15
Current: $1.32
Upside: +1,036.36%
Mar 11, 2025
Reiterates: Buy
Price Target: $25
Current: $4.32
Upside: +478.70%
Nov 26, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $35.49
Upside: +40.88%